UK:
Scrip Asks…What Does 2022 Hold For Biopharma? Part 2: Deal Making, M&A And Financial Markets
14 February 2022
Cooley LLP
To print this article, all you need is to be registered or login on Mondaq.com.
"Following two record-breaking years for biotech
fundraising, stock valuations are heading downwards. Biopharma
executives and industry experts surveyed by Scrip anticipate big
pharma executing more deals and acquisitions in 2022."
Read the article (subscription required)
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Corporate/Commercial Law from UK
The Next Charities SORP And FRS102 Update
Price Bailey
On 27 March 2024 the revised FRS102 was published. The effective date for most of the amendments is for accounting periods beginning on or after 1 January 2026...